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Study Objectives: The S-stereoisomer found in racemic albuterol may have associated 
proinﬂ  ammatory properties. We tested the hypothesis that airway inﬂ  ammation as assessed 
by exhaled nitric oxide is no different in patients with COPD when using racemic albuterol 
relative to levalbuterol or placebo.
Measurements: Twelve mild to moderate COPD patients were assigned to ﬁ  ve days each of 
nebulized racemic albuterol, levalbuterol, and saline placebo. Before and after each course of 
treatment, airway inﬂ  ammation was assessed via exhaled nitric oxide breath testing. Secondary 
functional outcomes that were measured included spirometry, a functional assessment utilizing 
a six-minute walk, and symptoms score using the University of California, San Diego Shortness 
of Breath Questionnaire.
Results: There was no statistically signiﬁ  cant difference in pre and post FeNO levels within 
and between treatment groups (p = 0.121). There were also no signiﬁ  cant differences within 
or between treatment groups for the secondary outcome measurements of FEV1 (p = 0.913), 
functional assessment utilizing a six-minute walk (p = 0.838) and the symptom scores using 
Shortness of Breath Questionnaire (p = 0.500).
Conclusion: We found no difference in mild to moderate COPD patients treated with racemic 
albuterol, levalbuterol or placebo for measurement of exhaled nitric oxide or the secondary 
outcomes that were measured. 
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Introduction
Chronic obstructive pulmonary disease (COPD) is a disease state characterized by 
airﬂ  ow limitation that is not fully reversible and progressive chronic inﬂ  ammation 
throughout the airways, parenchyma, and pulmonary vasculature (GOLD 2005). Various 
bronchodilator medications, to include the β2-agonists, are commonly used in treating 
COPD. β2-agonists bind to the β2-receptor and relax airway smooth muscle reducing 
airﬂ  ow obstruction. They are recommended both on a regular schedule and on an as 
needed basis (GOLD 2005).
Albuterol, a short-acting β2-agonist, is available as a racemic preparation that 
is composed of (R) and (S)-isomers in a 50:50 mixture or as a single (R)-isomer 
(levalbuterol). The (R)-isomer is predominantly responsible for the bronchodilator 
effect and side effects of tachycardia, tremor, and nervousness (Handley 2001). 
The (S)-isomer, considered inert due to its weak binding to the β2-adrenoceptor, 
has been reported to have potentially deleterious effects (Handley 1999, 2001; Page 
and Morley 1999) to include the promotion of bronchoconstriction and bronchial International Journal of COPD 2006:1(4) 462
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hyperresponsiveness (Mazzoni et al 1994; Wang et al 1994; 
Gauvreau et al 1997; Templeton et al 1998). In addition, the 
(S)-isomer has been reported to have various proinﬂ  ammatory 
effects including alterations in cytokine production (Gavreau 
et al 1997; Frieri et al 2000; Cho et al 2001; Baramki et al 
2002), enhanced production of histamine (Cho et al 2001), 
immune cell proliferation/activation (Manolitsas et al 1995; 
Morley et al 1995; Gauvreau et al 1997; Volcheck et al 1998; 
Baramki et al 2002), and increased nitric oxide release in 
stimulated small airway epithelial cells (Frieri et al 2000). 
As chronic inﬂ  ammation can contribute to accelerated loss 
of lung function, the use of levalbuterol has been considered 
due to concern about the inflammatory potential of the 
(S)-isomer (Costello 1999). Although information exists 
suggesting that the (S)-isomer may induce inﬂ  ammation in 
the setting of asthma, to our knowledge, there are no studies 
investigating the presence of inﬂ  ammatory response in the 
setting of COPD. In this study, we tested the hypothesis that 
airway inﬂ  ammation, as measured by exhaled nitric oxide, is 
no different in COPD patients when sequentially comparing 
nebulized racemic albuterol, levalbuterol, or placebo.
Airway inﬂ  ammation was assessed by measurement of the 
fraction of exhaled nitric oxide (FeNO), a marker of airway 
inﬂ  ammation. Relative to baseline levels or normal controls, 
elevated FeNO levels have been documented in the setting of 
COPD (Agusti et al 1999; Corradi et al 1999; Ansarin et al 
2001; Kharitonov and Barnes 2004), chronic bronchitis (Delen 
et al 2003) and COPD exacerbations (Maziak et al 1998; 
Agusti et al 1999). Additionally, inhaled corticosteroids have 
been shown to reduce baseline levels of elevated FeNO in 
stable COPD (Zietkowski et al 2005), suggesting that FeNO 
may serve as a surrogate measure of chronic perseverant 
airway inﬂ  ammation at baseline that is ameliorated through 
the use of inhaled corticosteroids. 
Methods
The study was conducted at Wilford Hall Medical Center and 
Brooke Army Medical Center in San Antonio, Texas. Patients 
18 years of age and older, who had at least a 10 pack year 
smoking history with no recent tobacco use within the six 
months preceding protocol enrollment, and mild to moderate 
COPD deﬁ  ned by a baseline forced expiratory volume in one 
second (FEV1)/forced vital capacity (FVC) ratio of less than 
0.70 and an FEV1 greater than 50% predicted were enrolled 
in the study. The Brooke Army Medical Center Institutional 
Review Board approved the study, and all patients gave 
written informed consent. 
Twelve patients were enrolled for the study. They were 
randomized, but not blinded, to complete three separate ﬁ  ve-
day treatments. The treatment groups consisted of albuterol 
(2.5 mg four times daily), levalbuterol (0.63 mg three times a 
day with one saline placebo dose), and 5 ml of saline placebo 
four times daily. All medications were administered through 
a nebulizer machine (PARI LC nebulizer, Midlothian, 
VA) that the patients took home with them. Each patient 
received instruction in how to properly use the nebulizer 
device and administer the medication. They were also 
instructed to complete a diary at home that recorded their 
use of medication. There was a minimal two day washout 
period between treatment groups during which the patients 
abstained from medications intended to treat COPD. All 
patients were provided with an albuterol metered dose inhaler 
(MDI) which could be used for “rescue” purposes at any time 
during the study. However, rescue inhaler use constituted 
ground for exclusion from further study participation. None 
of the participants used a rescue treatment throughout the 
course of the study.
Patients were excluded from the study if they had had an 
exacerbation of their COPD requiring an adjustment in their 
COPD medications, the addition of an oral corticosteroid, 
or the administration of antibiotics, within the 6 months 
prior to trial enrollment. Patients were also excluded if 
they had a history of hospitalization due to COPD. Further 
exclusion criteria included use of an inhaled corticosteroid 
regimen or phosphodiesterase inhibitor (ie, theophylline) 
within the previous one month, use of an oral β-blocker 
medication, long-acting inhaled β-agonist, antihistamine, or 
nasal corticosteroid within the preceding week of, or during, 
trial participation. Patients could not have evidence of a 
concurrent restrictive lung disease on pulmonary function 
testing, or 12% or greater improvement in FEV1 following 
administration of a bronchodilator. All patients who 
experienced a COPD exacerbation during the study interval 
were excluded from continuing the study (n = 1). 
The primary outcome of the study was the measurement 
of FeNO. Based on a previous study (Agusti et al 1999) in 
clinically stable COPD patients following exacerbation, we 
assumed a mean exhaled nitric oxide level of 15.8 ± 3.8 parts 
per billion at baseline. An increase of FeNO by 2.4 standard 
deviations was considered to be signiﬁ  cant. Our study was 
powered at 80% to detect this difference with a level of 
conﬁ  dence of 95%. Nine subjects acting as their own control 
were needed to detect a difference with the desired level of 
power and conﬁ  dence. International Journal of COPD 2006:1(4) 463
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FeNO measurements were made using a NIOX® nitric 
oxide monitoring system (Aerocrine AB, Sweden) using a 
ﬂ  ow rate of 50 ml/sec and reported as parts per billion (ppb). 
FeNO levels were measured both before and after completion 
of each treatment group and were carried out in accordance 
with the guidelines published by the American Thoracic 
Society (ATS 1999).
Secondary outcomes that were measured included 
spirometry, a functional assessment utilizing a six-minute 
walk, and symptom score using the University of California, 
San Diego Shortness of Breath Questionnaire (SOBQ) (Eakin 
et al 1998). A Sensorimedics 6200 machine was used for 
spirometry to record FEV1, FVC, and FEV1/FVC ratio. The 
six-minute walk test (6MWT) was conducted in accordance 
with the guidelines described by the American Thoracic 
Society in their 2002 Ofﬁ  cial Statement (ATS 2002). A 
MeterMan measuring wheel (Model 1212) was used to 
measure the distance covered by the patient in the six-minute 
period. A difference of 54 meters in the six-minute walk 
distance was considered to be clinically signiﬁ  cant based 
on previous estimates (Redelmeier et al 1997). The SOBQ 
was used with permission from the University of California, 
San Diego Medical Center’s Pulmonary Rehabilitation 
Program. Based on previous recommendations a change of 
5 units for the SOBQ was considered to be a minimal 
clinically important difference (Kupferberg et al 2005). 
Secondary outcome measurements were obtained at the 
completion of each treatment group and compared with 
baseline measurements.
Data were analyzed using SPSS Sample Power, Version 
2.0 (SPSS Inc, Chicago, IL). The distributions of the FeNO 
values were not signiﬁ  cantly different from normal on the 
Kolmogorov-Smirnov test (p > 0.05) and were therefore 
analyzed with parametric testing. Paired t-test was used to 
assess differences in FeNO between times within treatments. 
Repeated measures of ANOVA using paired t-test on FeNO, 
FEV1, and six minute walk by treatment were used for 
between group comparisons. The Hyun-Feldt statistic was 
used to analyze the summed SOBQ scores for between group 
comparisons as the data were not normally distributed.
Results
Patient characteristic data is shown in Table 1. The average 
age of our patients was seventy years and ranged from ﬁ  fty-
ﬁ  ve to eighty. There were nine males and three females. All 
patients had a baseline obstructive FEV1/FVC ratio less than 
0.70. Baseline FEV1s were normal in four patients, mild in 
ﬁ  ve, and moderate in three. Ten patients completed the study. 
One patient withdrew secondary to transportation issues. 
Another withdrew secondary to a COPD exacerbation that 
occurred while receiving placebo, which required treatment. 
No other patients reported use of albuterol for “rescue” 
purposes during the course of the study.
The mean pre- and post-treatment FeNO levels for all 
patients in each treatment group are listed in Table 2. The data 
are represented in an intention-to-treat format and include 
the two participants who were eventually excluded from 
the trial. Due to the constraints of the statistical methods, 
the remaining calculations only include the 10 subjects who 
completed the study. In an analysis of those patients, the 
mean FeNO levels and standard deviation were as follows: 
levalbuterol (pre- 27.3 ± 19.1 ppb; post- 26.1 ± 20.6 ppb), 
albuterol (pre- 30.6 ± 24.4 ppb; post- 28.9 ± 22.4 ppb), and 
placebo (pre- 26.9 ± 20.5 pbb; post- 23.8 ± 15.0 ppb). The 
between-group comparisons in FeNO are noted in the 
box plot in Figure 1. There was no statistically signiﬁ  cant 
difference in FeNO between treatment groups (p = 0.121). 
Patient number twelve was an outlier and upon re-review 
of the patient’s medical records and condition we were not 
able to explain the elevation in FeNO. This patient’s data 
were included in the analysis. Repeated analysis of treatment 
effect with subject number twelve excluded did not change 
the signiﬁ  cance of our ﬁ  ndings. 
Results for the secondary outcome measurements are 
listed in Table 3. There were no differences within or between 
treatment groups for FEV1 (p = 0.913), functional assessment 
utilizing the 6MWT (p = 0.838) and symptom scores using 
the SOBQ (p = 0.500). Complete SOBQ data were available 
for eight patients. There was a 6.25 and 4 unit increase in 
the SOBQ score with levalbuterol and albuterol respectively 
compared with baseline.
Discussion
Given the associated proinﬂ  ammatory potential of the (S)-
isomer of albuterol, our study was designed to determine if 
Table 1 Subject characteristics (n =12)
Average age: years (range)  70 (55–80)
Male 9
Female 3
FEV1 > 80% predicted  4
FEV1 66%–79% predicted  5
FEV1 50%–65% predicted  3
Abbreviations: FEV1, forced expiratory volume in one second. International Journal of COPD 2006:1(4) 464
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airway inﬂ  ammation, as measured by FeNO, was different 
in patients with COPD treated with albuterol compared with 
levalbuterol or placebo. We anticipated to measure a rise 
in FeNO if the (S)-isomer of albuterol was associated with 
induction of inﬂ  ammation. In addition, we sought to determine 
if there were signiﬁ  cant differences in racemic albuterol or 
levalbuterol relative to placebo in terms of improvement in 
spirometry, functional assessment utilizing a 6MWT, and 
symptom scores using the SOBQ. 
We found no difference within or between treatment groups 
for measurement of FeNO, spirometry, functional capacity, 
or symptom scores. However, there was a 6.25 and 4 unit 
increase in the SOBQ score with levalbuterol and albuterol, 
respectively, compared to baseline. A ﬁ  ve unit increase of the 
SOBQ score has previously been reported to represent a minimal 
clinically important difference suggesting levalbuterol may 
have provided a clinically signiﬁ  cant improvement in dyspnea. 
However, these conclusions are limited by the open-label 
property of the study. 
Of note, the amount of (R)-isomer in 2.5 mg of racemic 
albuterol is 1.25 mg, which is higher than the equivalent 
(R)-isomer dose of 0.63 mg used in the levalbuterol arm 
of the study. This could have limited our ability to ﬁ  nd 
signiﬁ  cant differences in the utilized functional secondary 
outcome measures. However, by using the higher dose 
of racemic albuterol, we administered a larger amount of 
(S)-isomer, which should have ampliﬁ  ed any (S)-isomer 
associated difference in attendant airway inﬂ  ammation, if 
present. No increase in airway inﬂ  ammation, as measured by 
FeNO, was found with this higher dose of albuterol.
Our study had some limitations. Our study subjects’ 
baseline FeNO levels were higher than we initially assumed. 
This may have limited the sensitivity of the study. In addition, 
the small sample size may have limited our ability to detect 
a difference in FeNO levels if one existed. Also, the patients 
were not blinded to the treatment groups, which may have 
inﬂ  uenced the reporting of effort or subject-related measures 
such as walking effort or symptom score reporting. However, 
this should not have inﬂ  uenced the primary outcome measure 
of FeNO. A majority of our subjects had relatively mild 
disease, which may have limited our ability to detect clinically 
signiﬁ  cant differences in the secondary outcomes that were 
Table 2 Mean pre- and post-exhaled nitric oxide levels 
(parts per billion)
  Pre Post  P  value
Levalbuterol  28.5 (± 18.6)  27.4 (± 20.0)  0.581
Albuterol  29.9 (± 23.2)  28.7 (± 21.2)  0.530
Placebo  25.8 (± 18.9)  24.3 (±14.3)  0.609
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Figure 1 Box-plot of FeNO by treatment and time. The median is the dark line within each box. Each box is deﬁ  ned by the 25th and 75th percentiles so 50% of cases 
have values within the box. The error ﬂ  ags represent the largest and smallest observed values that are not outliers. No signiﬁ  cant differences were noted between 
groups (p = 0.121).
Notes: oOutliers are values more than 1.5 box-lengths from the quartile; *Extremes are values more than 3 box-lengths from the quartiles.
Abbreviations: FeNO, fraction of exhaled nitric oxide. International Journal of COPD 2006:1(4) 465
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measured. Lastly, the length of time on each therapy may 
not have been enough to cause a signiﬁ  cant change in airway 
inﬂ  ammation that could be detected by FeNO.
The prospects for improved therapy in COPD by the use 
of levalbuterol have been discussed previously (Costello 
1999). Despite the theoretical advantages there have 
been few studies addressing the potential usefulness of 
levalbuterol in the management of COPD. In a study by 
Truitt and colleagues (2003), levalbuterol demonstrated a 
clinical and economic advantage over racemic albuterol in 
the treatment of hospitalized patients with COPD and asthma, 
although the signiﬁ  cance of this ﬁ  nding has been brought 
into question (Hendeles 2003). Another study by Datta and 
colleagues (2003) found no advantage of using levalbuterol 
over conventional nebulized bronchodilators in single dose 
for as needed treatment in stable COPD. 
In conclusion, our study found no evidence of increased 
airway inﬂ  ammation with the use of racemic albuterol compared 
with levalbuterol as determined by measurement of FeNO. 
In addition, there were no signiﬁ  cant differences between 
levalbuterol and racemic albuterol in the secondary outcomes 
that were measured. As a whole, levalbuterol does not appear to 
be more advantageous than racemic albuterol for the treatment 
of COPD. Without a clearly derived beneﬁ  t, the routine use of 
levalbuterol for the management of  COPD is not recommended 
at this time. Further studies with more subjects and a longer 
treatment period are needed to conﬁ  rm these results.
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